Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
Harvard Business School
Merck
Moodys

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR DELSTRIGO


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Delstrigo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02629822 ↗ Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) Completed Merck Sharp & Dohme Corp. Phase 2 2016-01-14 The primary objectives of this study are to evaluate the antiretroviral activity and the safety/tolerability of open-label doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF; MK-1439A; DELSTRIGO™) consisting of a single fixed-dose combination (FDC) tablet of DOR/3TC/TDF 100 mg/300 mg/300 mg in treatment-naïve HIV-1 infected participants with select non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted resistance-associated mutations.
NCT04233372 ↗ Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study Recruiting Dr. Josep Mallolas Phase 4 2020-08-27 Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
NCT04233372 ↗ Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study Recruiting David Garcia Cinca Phase 4 2020-08-27 Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
NCT04283656 ↗ Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women Not yet recruiting Thomas Jefferson University Phase 1 2022-01-03 Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone.
NCT04429152 ↗ ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance Recruiting Professor Francois Venter Phase 3 2021-02-09 This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance
NCT04429152 ↗ ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance Recruiting Willem Daniel Francois Venter Phase 3 2021-02-09 This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance
NCT04433780 ↗ DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV Recruiting Professor Francois Venter Phase 3 2021-01-04 This is a pilot study investigating the safety of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in women of reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy on metabolic and neuropsychiatric outcomes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Delstrigo

Condition Name

Condition Name for Delstrigo
Intervention Trials
Hiv 5
HIV-1-infection 2
Human Immunodeficiency Virus 2
Obesity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Delstrigo
Intervention Trials
HIV Infections 4
Acquired Immunodeficiency Syndrome 4
Body Weight 3
Weight Gain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Delstrigo

Trials by Country

Trials by Country for Delstrigo
Location Trials
United States 7
Spain 3
United Kingdom 2
South Africa 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Delstrigo
Location Trials
Pennsylvania 1
New Jersey 1
Maryland 1
Illinois 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Delstrigo

Clinical Trial Phase

Clinical Trial Phase for Delstrigo
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Delstrigo
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 4
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Delstrigo

Sponsor Name

Sponsor Name for Delstrigo
Sponsor Trials
Professor Francois Venter 2
Willem Daniel Francois Venter 2
Merck Sharp & Dohme Corp. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Delstrigo
Sponsor Trials
Other 14
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
McKinsey
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.